Bendamustine
Metastatic Malignant Solid Neoplasm
Fred Hutchinson Cancer CenterSmall moleculePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
74 Active assets in the Metastatic Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
Nivolumab Fred Hutchinson Cancer Center | Phase 3 | BB |
Abemaciclib National Cancer Institute (NCI) | Phase 3 | B |
Carboplatin Revolution Medicines, Inc. | Phase 2 | B |
TEONANACATL University of Washington | Phase 2 | B |
View all 50 →
Same molecule, other indications
Bendamustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →